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Amino acids generated from the catabolism of hemoglobin by
intra-erythrocytic malaria parasites are not only essential for
protein synthesis but also function in maintaining an osmoti-
cally stable environment, and creating a gradient by which
amino acids that are rare or not present in hemoglobin are
drawn into the parasite fromhost serum.Wehave proposed that
a Plasmodium falciparumM17 leucyl aminopeptidase (PfLAP)
generates and regulates the internal pool of free amino acids and
therefore represents a target for novel antimalarial drugs. This
enzyme has been expressed in insect cells as a functional 320-
kDa homo-hexamer that is optimally active at neutral or alka-
line pH, is dependent on metal ions for activity, and exhibits a
substrate preference for N-terminally exposed hydrophobic
amino acids, particularly leucine. PfLAP is produced by all
stages in the intra-erythrocytic developmental cycle of malaria
but was most highly expressed by trophozoites, a stage at which
hemoglobin degradation and parasite protein synthesis are ele-
vated. The enzyme was located by immunohistochemical meth-
ods and by transfecting malaria cells with a PfLAP-green fluo-
rescent protein construct, to the cytosolic compartment of the
cell at all developmental stages, including segregated merozo-
ites. Amino acid dipeptide analogs, such as bestatin and its
derivatives, are potent inhibitors of the protease and also block
the growth of P. falciparum malaria parasites in culture. This
study provides a biochemical basis for the antimalarial activity
of aminopeptidase inhibitors. Availability of functionally active
recombinant PfLAP, coupled with a simple enzymatic readout,
will aid medicinal chemistry and/or high throughput
approaches for the future design/discovery of new antimalarial
drugs.
The intra-erythrocytic stage of the malarial parasite Plasmo-
dium falciparum is responsible for many of the clinical symp-
toms attributable to a disease that kills 2–3million per year (1).
It also represents a stage during which many metabolic path-
ways, unique to the parasite, are switched on and as a result has
been the focus of themajority of antimalarial drug development
strategies (2, 3). One essential pathway that has been a particu-
lar target for antimalarial drug discovery is the catabolism of
erythrocyte hemoglobin; between 65 and 75% of the host cell
hemoglobin is degraded in a process that results in the libera-
tion of free amino acids (4–6). These free amino acids are uti-
lized in a variety of critical processes including the following: (a)
parasite protein synthesis and development (7), (b) themain-
tenance of osmotic pressure within the infected red blood
cell that prevents premature cell lysis during the highly met-
abolic maturation and replication phases (8), and (c) the pro-
vision of a pool of free amino acids that serve as a concen-
tration gradient against which an influx of amino acids that
are rare or not present in hemoglobin enter the malaria-
infected erythrocyte from host serum (9, 10). Although
malaria parasites can acquire amino acids from the external
environment, studies by Liu et al. (11) recently demon-
strated that hemoglobin digestion is necessary for parasite
survival and that this process alone can supply the parasite
with most of its amino acid requirements.
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The initial steps in the catabolism of host hemoglobin take
place within the acidic digestive vacuole (DV)5 of the parasite
and involve a number of endopeptidases of variousmechanistic
classes, including aspartic proteases (plasmepsins I, II, and IV),
cysteine proteinases (falcipains 2, 2, and 3), and a metallopro-
tease (falcilysin) (7, 12). An exopeptidase, dipeptidyl-amino-
peptidase I, or cathepsinC, also exists in theDVand, as its name
implies, can reduce peptides generated by endopeptidase activ-
ity to dipeptides (13). Studies usingP. falciparumdemonstrated
that soluble lysates ofDVs could degrade humanhemoglobin to
small peptide fragments but were incapable of liberating free
amino acids (14). In contrast, when human hemoglobin was
incubated with cytosolic extracts, the main products generated
were free amino acids suggesting the presence of an exopepti-
dase activity (mono-, di-, tri-, and carboxypeptidases) in this
cellular compartment. These observations also imply that small
peptide fragments derived from hemoglobin degradation are
transported from the DV to the parasite cytosol for processing
into free amino acids by these enzymes (14–16).
A number of reports have characterized aminopeptidase
activity in cytosolic extracts of several Plasmodium species
(15–22). The activity was optimum at neutral pH, inactive
below pH 6.0, and had a preference for synthetic substrates
containing leucine and alanine at theN terminus (15, 16). These
biochemical properties are consistent with an enzymatic func-
tion outside the DV and a proposed role in the terminal stages
of hemoglobin catabolism because leucine and alanine consti-
tute 24% of the amino acids in this protein. Furthermore, a
partially purified P. falciparum aminopeptidase was capable of
freeing amino acids from synthetic peptides representative of
the products of endopeptidase-degraded hemoglobin, and was
inactivated by the specific aminopeptidase inhibitors bestatin
and nitrobestatin (16). These same inhibitors arrested the
growth of Plasmodium chabaudi chabaudi and P. falciparum
parasites in vitro, most particularly at the intra-erythrocytic
trophozoite stages that express the highest aminopeptidase
activity (16, 21).
Although a total of eight aminopeptidases have been identi-
fied among the annotated sequences of the 26-Mb P. falcipa-
rum genome (23), only two belong to families of neutral
aminopeptidases as follows: a 67.8-kDa M17-family leucyl
aminopeptidase (PF14_0439), and a 122-kDa M1-family ala-
nyl aminopeptidase (MAL13P1.56). The M17 aminopepti-
dases are classically described as cytosolic enzymes, whereas
the M1 aminopeptidases are typically membrane-bound;
however, Florent and co-workers (22) detected M1 alanyl
aminopeptidase activity in soluble extracts of P. falciparum
and used antipeptide antibodies to identify 98- and 68-kDa
immunoreactive processed forms of the parent 122-kDa
membrane-bound aminopeptidase. In an attempt to identify
whether the M17 or M1 aminopeptidase, or both, was the
target of the bestatin-mediated killing of P. falciparum, we
generated transgenic parasites that overexpressed these ami-
nopeptidases (10). Only the parasites overexpressing the M17
leucyl aminopeptidase gene produced a functional enzyme,
whereas theM1 aminopeptidase transgenic parasites produced
an inactive protein of 120 kDa that did not process to smaller
fragments. The transgenic P. falciparum parasites overexpress-
ing the M17 aminopeptidase were less susceptible to killing by
bestatin when compared with wild-type parasites pinpointing
this enzyme as a target for this antimalarial inhibitor (10).
In this study we have successfully produced a functionally
active recombinant form of the malaria M17 leucyl aminopep-
tidase, rPfLAP, and report for the first time its physico-bio-
chemical properties, cellular expression, and distribution. We
interpret our findings in the light of previously published
reports of aminopeptidase activities in extracts of malaria par-
asites. We also show that the aminopeptidase inhibitor, besta-
tin, and other dipeptide analogs are potent inhibitors of rPfLAP
and prevent the growth of P. falciparum parasites in vitro. Our
data provide further support for designating the M17 leucyl
aminopeptidase as a promising target for new antimalarials.
EXPERIMENTAL PROCEDURES
Parasite Culture—The asexual intra-erythrocytic stages of P.
falciparum parasites were cultured in RPMI 1640medium con-
taining 10% human serum (24). The parasites used were D10, a
noncytoadherent clone of FC27 lacking the right end of chro-
mosome 9 (25), and were obtained from the Walter and Eliza
Hall Institute, Melbourne, Australia. The parasites were syn-
chronized using two rounds of sorbitol treatment (26), and
stage-specific parasites were harvested at ring stage, early tro-
phozoite stage, late trophozoite stage, and schizont stage.
The P. falciparumM17 Leucyl Aminopeptidase Gene, Codon
Optimization, andGene Synthesis—TheM17 leucyl aminopep-
tidase gene sequence (Pf14_0439), as annotated by PlasmoDB,
is located on chromosome 14 of P. falciparum. It consists of a
single exon of 1818 bp encoding a 605-amino acid protein. The
gene was amplified from genomic DNA using primers
described below but was also chemically synthesized by GENE-
ART GmbH (GeneArt, Germany) using codons for optimized
gene expression in the yeast Pichia pastoris. PotentialN-linked
glycosylation sites were removed in gene synthesis by replacing
the asparagine of all Asn-X-(Thr/Ser) motifs with Glu. These
genes were ligated into pCR-Script cloning vector (Stratagene,
CA).
Plasmid Construction and Transfection into Parasites—For
the transgenic expression of PF14_0439-GFP under the control
of the hsp86 promoter, the completeM17 aminopeptidase gene
PF14_0439 was amplified from D10 DNA using primers M17F
(AGATCTATGTATTTTTCTTCCTTATGT), which con-
tained a BglII restriction site (in boldface), and M17R (CTG-
CAGTAGAGCGTCATTGAGTACAAA), which contained a
PstI site (in boldface), but not the putative stop codon of the
gene. The gene was cloned into pHGB Gateway Entry vector
containing the hsp86 promoter region and modified to contain
BglII/PstI sites between the promoter and the GFP (gift from
Dr. Chris Tonkin). This entry vector containing the
PF14_0439-GFP sequence was used in a ClonaseTM reaction
(Invitrogen) with a pHHC*/DR0.28 vector containing a desti-
5 The abbreviations used are: DV, digestive vacuole; H-Leu-NHMec, L-leucine-
4-methylcoumarinyl-7-amide; GFP, green fluorescent protein; mFu, milli-
fluorescent units; PBS, phosphate-buffered saline; HPLC, high pressure liq-
uid chromatography; PfLAP, P. falciparum M17 leucyl aminopeptidase;
LAP, leucyl aminopeptidase; rPfLAP, recombinant PfLAP; Ni-NTA, nickel-
nitrilotriacetic acid; LCR, low complexity region.
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nation cassette to obtain vectors mediating expression of
PF14_0439-GFP fusion proteins under the hsp86 promoter.
Inserts of all constructs were confirmed by sequencing. Ring
stage parasites were subjected to electroporation in the pres-
ence of 150g of plasmid as described (27, 28). Parasites resist-
ant to WR99210 were obtained 15–22 days later.
Expression of Recombinant Malarial M17 Leucyl Aminopep-
tidase in Insect Cells—Successful functional expression of the
M17 leucyl aminopeptidase (PfLAP) was achieved using a trun-
cated form of the enzyme (Fig. 1A). This truncated form was
prepared from the synthesized codon-biased leucyl aminopep-
tidase gene andwas amplified by PCR using 5 primers contain-
ing the additional bases CACC to allow directional cloning of
the gene into the Gateway entry vector pENTR/D-TOPO
(Invitrogen). The primers used were as follows: LAP forward
5-CACCATGGCTTCTGAGGTTCCAC-3, and LAP reverse
5-GCCCTGAAAATACAGGTTTTCCAAAGCGTCGTTC-
AAAAC-3. The pENTR construct housing the truncated
leucyl aminopeptidase, pENTR-LAP, was verified by DNA
sequencing. The verified construct was recombined with Bacu-
loDirectTM C-Term linear DNA (Invitrogen) and transfected
into Sf9 (Spodoptera frugiperda) cells according to the manu-
facturer’s protocol to generate the recombinant baculovirus
carrying the aminopeptidase gene. Sf9 insect cells were main-
tained in serum-free Sf-900II medium (Invitrogen) suspension
cultures at 28 °C and orbiting at 120 rpm on a shaker platform.
For protein expression, Sf9 insect cells were infected at the cell
density 3 106 cells/ml with rPfLAP recombinant baculovirus
at an multiplicity of infection of 2–5 plaque-forming units/cell.
The infections were allowed to proceed for 48 h at 28 °C before
the cell pellets were being harvested by centrifugation at
8,000 g for 15 min at 4 °C.
Purification andMolecular Size Analysis of rPfLAP—Baculo-
virus cells (3.5 106 cells/ml) containing rPfLAPwere stored
as15-ml pellets at80 °C. The pellet was thawed on ice and
resuspended in cold PBS to a total volume of 100 ml. The sus-
pension was sonicated three times for 10 s at 2-min intervals
using a soni-probe. The suspension was frozen, thawed and
sonicated an additional two times. The suspension was then
centrifuged at 14,000 g in a Sorvall RC-5 centrifuge for 30min
at 4 °C. The supernatant or soluble extract was filtered on ice
through 0.45-m HA Millipore membrane. The 85-ml filtrate
was diluted to a total volume of 425 ml with 50 mM sodium
phosphate buffer, pH 8.0, containing 300 mM sodium chloride
and 10 mM imidazole. The resulting protein solution was
loaded on a 1-ml nickel-agarose column equilibrated with the
same buffer. A sample of the eluate or flow-through was stored
for SDS-PAGE analysis. The column was then washed with 10
ml of 50 mM sodium phosphate buffer, pH 8.0, containing 300
mM sodium chloride and 20 mM imidazole. Leucyl aminopep-
tidase was eluted from the column in a total volume of 10ml by
addition of 50mM sodium phosphate buffer, pH 8.0, containing
300 mM sodium chloride and 250 mM imidazole to the column.
The eluatewas dialyzed against PBS containing 10MZnCl2 for
16 h. Protein concentration of purified enzyme was measured
using the Bio-RadDCprotein assay based on the Lowrymethod
(29). Bovine serum albumin was the protein standard.
Purified rPfLAP and soluble extracts of malaria parasites
(80% trophozoites; prepared as for described for extraction of
insect cells above) were analyzed using a Smart System (Amer-
sham Biosciences) HPLC equipped with a Superdex-200 gel
filtration column. The samples (40 l containing 10–20 g of
protein) were passed through the column at a flow rate of 40 l
per min and collected each minute into tubes pre-loaded with
40l of 1 mMCoCl2 in 50mMTris-HCl, pH 8.0. Fractions were
analyzed for aminopeptidolytic activity toward H-Leu-NHMec
and Ala-NHMec as described below. Separation of the molec-
ular size standards of apoferritin (440 kDa), -amylase (232
kDa), bovine serum albumin (67 kDa), and carbonic anhydrase
(29 kDa) was monitored at A280. The molecular size of the
PfLAP and enzymes in the parasite soluble extracts was calcu-
lated from a plot of log Mr versus elution time for these
standards.
Enzymatic Analysis—Aminopeptidase activity was deter-
mined by measuring the release of the fluorogenic leaving
group, NHMec, from a range of fluorogenic peptide substrates
representative of the various amino acid groupings. Reactions
were carried out in 96-well microtiter plates (200 l total vol-
ume, 30 min, 37 °C) using a spectrofluorimeter (Bio-Tek KC4)
with excitation at 370 nm and emission at 460 nm. Enzyme was
incubated in 50 mM Tris-HCl, pH 8.0, and containing 1 mM
CoCl2 for 20 min before the addition of 10 MH-Leu-NHMec.
Initial rates were obtained at 37 °C over a range of substrate
concentrations spanning Km values (0.2–500 M) and at fixed
enzyme concentrations in 50 mM Tris-HCl, pH 8.0. Inhibition
experiments were carried out in the presence of substrate.
Because bestatin and its analogs are time-dependent inhibitors
of PfLAP, progress curves were monitored until a final steady-
state velocity, vs, was reached. Ki values were determined from
Dixon plots of 1/vs versus inhibitor concentration when [S]
Km.
The metal ion dependence of PfLAP was determined by
assaying activity after preincubation of the enzyme (10 min,
37 °C) in 50 mM Tris-Cl, pH 8.0, containing a given metal chlo-
ride, before addition of H-Leu-NHMec substrate (10 M). The
PfLAP apoenzyme was prepared by incubation of the enzyme
with 10 mM o-phenanthroline in PBS for 15 h, followed by dial-
ysis against PBS overnight. The ability of metal cations to reac-
tivate the PfLAP apoenzyme was determined by assaying its
activity following preincubation (10 min, 37 °C) with 0.1 mM
metals. Inhibition of PfLAP activity by peptidase inhibitors was
investigated by preincubating the enzyme (10 min, 37 °C) with
EDTA and o-phenanthroline in 50 mM Tris-Cl, with and with-
out 0.5 mM CoCl2.
Northern Blotting—Northern blotting was carried out using
total RNA extracts from stage-specific parasites (30, 31). The
blot was probed with a DNA fragment corresponding to the
full-lengthM17 leucyl aminopeptidase (PF14_0435) DNA cod-
ing sequence labeled with [-32P]dATP by random priming
(DECAprime II Ambion). The blots were then stripped and
re-probed with the P. falciparum S28 RNA probe to ensure
equal loading in the lanes.
Polyclonal Antibody Production, Immunofluorescence Assays,
and Immunoblotting Analyses—A 15-mer peptide C*AGVSWN-
FKARKPKGcorresponding to the amino acids residues 577–590
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of the M17 leucyl aminopeptidase (PF14_0439) was synthe-
sized (Sigma) and conjugated to diphtheria toxin through the
N-terminally added cysteine residue. Mice were then immu-
nized three times at 3-week intervals with 30–50g of peptide-
diphtheria toxin conjugate per injection formulated in Freund’s
Complete and Incomplete Adjuvant (10). Antibodies were also
prepared in a similar manner to a recombinant PfLAP
expressed in Escherichia coli BL21 (DE3).
Immunofluorescence assays were carried out as described
before (32) using air-dried P. falciparum-infected red blood
cells fixed with acetone. Cells were probed with mouse anti-
M17 peptide (1/250) and thenCy2-conjugated goat anti-mouse
AffiniPure antibodies (Jackson ImmunoResearch). The para-
site nuclei were visualized with Hoechst dye (0.5 g/ml). Sam-
ples were viewed on an Axioscope 2 Mot  (Zeiss) equipped
with a Zeiss 63x/1.4 Plan Apochromat lens. Images were cap-
tured with an Axiocam MRm camera (Zeiss) using Axiovision
AC software (Zeiss). PF14_0435-GPF-tagged transgenic para-
sites were visualized in a live fluorescence assay.
Protein extracts were resolved on reducing SDS-polyacryl-
amide gels (10%) and transferred to 0.2-m polyvinylidene
difluoride membranes (Macherey-Nagel). Membranes were
probed with mouse anti-M17 peptide (1/250), stripped, and
reprobed with anti-P. falciparum glyceraldehyde-3-phosphate
dehydrogenase monoclonal antibodies (a kind gift of Dr. C.
Daubenberger, Swiss Tropical Institute, Basel, Switzerland)
diluted at 1/2000 to demonstrate equal loading (31). Sheep
horseradish peroxidase-conjugated anti-mouse secondary
antibodies (Chemicon) were used at 1/5000, and detection was
carried out using ECL (Amersham Biosciences).
In Vitro Sensitivity of Parasites to Aminopeptidase Inhibitors—
P. falciparum D10 parasites were cultured as described (24).
Stock solutions of inhibitors were prepared in 100% Me2SO.
The in vitro sensitivity of each parasite population to the amin-
opeptidase inhibitors bestatin {()-N-[(2S,3R)-3-amino-2-hy-
droxy-4-phenyl-butyryl]-L-leucine}, bestatin methyl ester, and
nitrobestatin was determined using [3H]hypoxanthine incor-
poration (33). Briefly, serial dilutions of each inhibitor were
prepared in culture media (0.05–50 M) and added with
[3H]hypoxanthine (0.5 Ci/well) to asynchronous cultures at
0.5% parasitemia and 2% hematocrit. After a 48-h incubation,
the amount of [3H]hypoxanthine incorporation was measured,
and the concentrations of inhibitor required to prevent incor-
poration by 50% (IC50) were determined by linear interpolation
of inhibition curves (34). Each assay was performed in triplicate
on three separate occasions.
Phlyogenetic Analysis of P. falciparum M17 Leucyl
Aminopeptidase—The C-terminal catalytic region sequence of
P. falciparum leucyl aminopeptidase (PF14_0439) (see Fig. 1A)
was used to search the BLASTP data base. Selected BLAST hits
were alignedwith the aid of ClustalWwithinMEGAversion 3.1
suite of programs (35). Regions of sequences that were difficult
to align because of gaps were removed using Gblocks.
Sequences were then realigned using ClustalW, and this align-
ment was then used to generate a phylogenetic tree. Phyloge-
netic analyses were conducted using MEGA version 3.1
(option: Neighbor-Joining, 1000 pseudo-replicates, and gaps
were handled by pairwise deletion and distances calculated
using Jones-Thornton-Taylor). To determine the strength of
the groupings, bootstrap values for nodes were calculated by
analyzing 1,000 bootstrap replicate data sets.
RESULTS
The P. falciparum M17 Leucyl Aminopeptidase Is Related to
Other ApicoplexanAminopeptidases—The general structure of
the P. falciparum M17 leucyl aminopeptidase (PfLAP) is pre-
sented as a schematic in Fig. 1A, and its primary sequence is
aligned with the LAPs of the various rodent (Plasmodium
berghei, P. chabaudi chabaudi, and Plasmodium yoelii) malaria
parasites in supplemental Fig. 1. The malaria LAPs are longer
than LAPs from most other species because of an N-terminal
extension containing an asparagine-rich low complexity region
(LCR) (residues 31–79). The N-terminal extensions are found
in each malaria leucyl aminopeptidase, but their sequences are
highly variable and of various lengths (supplemental Fig. 1).
Low complexity regions are found in many malarial proteins
and are linked to the high A  T richness of the genome and
high recombination rate (36).
Leucyl aminopeptidases of prokaryotes, plants, and animals
consist of two domains, a less conserved N-terminal domain
and a more conserved catalytic C-terminal domain. Evolution-
ary constraints are more stringent in the C-terminal domain
because it contains the active sitemotifs that generate a scaffold
capable of binding two zinc ions essential in substrate recogni-
tion (Fig. 1A). We assessed the phylogenetic relationship
between the P. falciparumM17 leucyl aminopeptidase and that
of its closest homologs by comparing their C-terminal catalytic
domains only (residues 280–598 in the P. falciparum sequence,
Fig. 1A). Fig. 1B shows that the P. falciparum leucyl aminopep-
tidase forms a distinct clade with various other Plasmodium
species.6 The overall sequence identity between the various
malaria LAPs is high (65–69%), and within the C-terminal
domain it is 80–85%. The residues that bind the metal ion are
thus highly conserved in malaria and most other LAPs (see
supplemental Fig. 1). Residues Asp-379, Asp-459, and Glu-461
bind zinc 1, whereas Lys-374, Asp-379, Asp-399, and Glu-461
bind zinc 2. The residues Lys-386 and Arg-463 that act as elec-
trophilic and proton donors, respectively, during the catalytic
process are also conserved.
The plasmodial M17 leucyl aminopeptidases form a distinct
group with other members of the Apicomplexa, including
Cryptosporidium homnis and Cryptosporidium parvum as well
6 Sequences used in this study were as follows: P. falciparum LAP (accession
number PF14_0439), P. yoelii LAP (accession number MALPY00521), P.
berghei LAP (accession number PB_RP3746, www.plasmodb.org), and P.
chabaudi chabaudi LAP (accession number PC_RP1908); C. hominis (acces-
sion number XP_667960), C. parvum (accession number XP_626197), T.
annulata (accession number CAI76586), T. gondii (accession number
80.m00088), Nostoc BAB77761; Synechococcus elongatus CAA73771, Sola-
num tuberosum CAA48038, Lycopersicon esculentum AA015916,Medicago
truncatula ABE92845; Arabidopsis thaliana NP_194821; Aquifex aeolicus
NP_211437; Clostridium tetani NP_782447; Bacillus cereus AAP11794; Cae-
norhabditis elegans LAP-1 P34629; L. major AAL16097; S. mansoni
AA502093; Rickettsia typhi AAU03616; E. coli PepA AP_004756; Anopheles
gambiae EA06020; Drosophila melanogaster AAF50390; Ciona intestinalis
149954 (orthoMCLDB internal accession); Fugu rubripesCA845956; Bovine
lens AAB28170; Homo sapiens LAP AAD17527; Mus musculus LAP
AAK13495; Rattus norvegicus AAH79381.
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as Theileria annulata and Toxoplasma gondii. The apicom-
plexan group in turn forms a larger cladewith variousM17 LAP
members of the flowering plants, which is not surprising given
their close association and common ancestry (37). The M17
leucyl aminopeptidase of the only other parasite in this phylo-
gram that uses hemoglobin as a source of nutrient, the human
blood fluke Schistosoma mansoni, resides in a more distant
clade, surprisingly grouping together with the M17 aminopep-
tidase of the protozoan Leishmania major.
Functionally Active Recombinant P. falciparum M17 Leucyl
Aminopeptidase Can Be Expressed in Insect Cells—Functional
expression of the full-length P. falciparum leucyl aminopepti-
dase was unsuccessful in prokaryotic (E. coli) and eukaryotic (P.
pastoris) expression systems (data not shown). A gene encoding
a truncated formof the enzyme (res-
idues 83–598; see Fig. 1A) that
lacked the asparagine-rich region
was produced, but it too was not
expressed in these systems. A simi-
larly truncated gene was then syn-
thesized using the codon bias of P.
pastoris, and with all potential gly-
cosylation sites removed, for the
purpose of expression in this yeast
system. Although this construct did
not produce a recombinant product
inP. pastoris, a recombinant protein
was finally obtained by transform-
ing insect cells with a baculovirus
vector carrying this modified gene.
The rPfLAP was easily extracted
and solubilized from the insect cells
by three cycles of freeze-thaw and
sonication andwas purified by affin-
ity chromatography on Ni-NTA-
agarose (Fig. 2A). The rPfLAP
resolved as a single protein of
expected approximate size, 60 kDa,
in reducing SDS-PAGE, and 15–25
mg of protein was obtained from a
1-liter fermentation. This purified
enzyme exhibited aminopeptidase
activity against the fluorogenic pep-
tide H-Leu-NMHec (Km  12.12
M) over the pH range 7–11, with
optimal activity at pH 8.5 and was
most stable when stored at alkaline
pH (Fig. 2, B and C).
rPfLAP Activity Is Dependent on
Metal Ions—Members of the M17
leucyl aminopeptidase family are
metalloproteases and therefore
require the presence of metal cat-
ions to maintain enzymatic activity
and stability (38–40). An analysis of
the metal requirement for rPfLAP
using the fluorogenic peptide
H-Leu-NHMec as a substrate
revealed that addition of Co(II) or Mn(II) ions to rPfLAP prior
to mixing with substrate increased its activity up to 24-fold
(Table 1). The divalent metal ions Ni(II), Mg(II), and Zn(II)
increased activity up to 10-, 8-, and 4-fold, respectively, whereas
various other ions enhanced activity no more than 2-fold. The
only divalent ion to have an inhibitory effect on enzymatic
activity was Cu(II) (1.0 mM).
Metal ions are clearly essential for the activity of rPfLAP, as
the metal chelator o-phenanthroline was capable of abolishing
enzyme activity (10 mM) in the presence or absence of Co(II)
ions (Table 2). EDTA was less effective at removing metal ions
from rPfLAP as 80% of enzymatic activity was retained even at
concentrations of 10 mM; however, this metal chelator was
capable of preventing activation of the enzyme by Co(II).
FIGURE 1. The P. falciparumM17 leucyl aminopeptidase. A, schematic showing the structure of the P. falcip-
arumM17 leucyl aminopeptidase, highlighting the asparagine-rich region unique tomalaria parasites, the less
conserved N-terminal domain, and the highly conserved C-terminal domain that contains all the residues that
make up the catalytic site. The arrow points to residue 83 where the functionally active recombinantly
expressed rPfLAPbegins. B, the phylogenetic relationship of the P. falciparumM17 leucyl aminopeptidasewith
othermembers of the family. The P. falciparum LAP (accessionnumber PF14_0439) forms a separate cladewith
otherM17 LAPs from P. yoelii, P. berghei, and P. chabaudi chabaudi. Themalaria LAPs aremost closely related to
enzymes from other apicomplexans such Crytosporidium hominis, C. parvum, T. annulata, and T. gondii.
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A preparation consisting largely of apoenzyme was prepared
by incubating the rPfLAP enzyme with o-phenanthroline fol-
lowed by dialysis to remove the metal ions and chelator com-
plex. The apoenzyme activity was reduced to 8% of the holoen-
zyme, but this was capable of re-activation by the addition of
metal cations; Co(II), Zn(II), and Mn(II) were most efficient at
reactivating the enzyme (Table 1). Reactivated enzyme, how-
ever, never returned to the value of the holoenzyme, which
suggests that removal of the metal ions can cause denaturation
of the protease.
rPfLAP andNative PfLAPAreHomohexameric Enzymes with
a High Specificity for N-terminal Leucines—Enzyme kinetics
studies using fluorogenic synthetic substrates revealed that,
consistent with its classification as a member of theM17 leucyl
aminopeptidase family, rPfLAP could efficiently cleave the
hydrophobic amino acid leucine from the N terminus of syn-
thetic peptides; its high affinity for this substrate is reflected in
both a low Km and a high kcat value resulting is a very high
overall catalytic efficiency, kcat/Km, of 3218 M1 s1 (Table 3).
The enzyme exhibited a marked preference for this amino acid
compared with the hydrophobic amino acid phenylalanine
(kcat/Km 183 M1 s1), and evenmore so to proline (kcat/Km
2.51 M1 s1). Aliphatic hydrophobic amino acids such as valine
FIGURE 2. Purification of functionally active P. falciparum M17 leucyl
aminopeptidase. A, purification of recombinant leucyl aminopeptidase was
monitored by 12% reducing SDS-PAGE. MW, molecular size markers; lane 1,
total freeze-thaw extract of insect cells infectedwith baculovirus carrying the
PfLAP gene; lane 2, insoluble pellet of recombinant insect cells; lane 3, soluble
supernatant extract of insect cells; lane 4, column run-through of Ni-NTA-
agarose column; lane 5, sample fromwash of Ni-NTA-agarose column; lane 6,
eluted purified rPfLAP from Ni-NTA-agarose column. Purified protein
migrates at 60 kDa, which is expected for the truncated form of rPfLAP indi-
cated in Fig. 1A. B, enzyme assays with the fluorogenic peptide substrate
H-Leu-NHMecdemonstrate that the rPfLAPexhibits typicalMichaelis-Menten
enzymatic kinetics with a Km constant of 12.12 M for this substrate. C, the
rPfLAP exhibits activity in the neutral to alkaline pH range, 6.5 to 11.0 (solid
diamonds), with a pH optimumat 8.2. The enzymewasmost stable in alkaline
pH (open squares) and could be stored for 4 weeks at 4 °C and at pH 7.3 with-
out significant loss of activity.
TABLE 1
Effect of divalent metal ions on recombinant P. falciparumM17
leucyl aminopeptidase (holoenzyme) and its metal-depleted
apoenzyme
Metal ion Concentration Relative activityHoloenzymea Apoenzymeb
mM %
None 100 8
Ca(II) 0.01 153	 5
0.1 140	 1 9
1 127	 3
Co(II) 0.01 1175	 6
0.1 2399	 70 322
1 2081	 46
Cu(II) 0.01 227	 11
0.1 173	 5 15
1 52	 2
Fe(II) 0.01 140	 11
0.1 211	 5 13
1 190	 17
Mg(II) 0.01 180	 10
0.1 422	 14 17
1 788	 11
Mn(II) 0.01 587	 23
0.1 1653	 26 57
1 2310	 24
Ni(II) 0.01 334	 2
0.1 594	 26 46
1 1002	 59
Zn(II) 0.01 374	 37
0.1 418	 6 128
1 420	 15
a100% activity is the rate of 73 mFu/s, and data reflect the mean relative activity	
S.D. (n 3).
b Data reflect the relative activity of PfLAP following treatment with o-phenanthro-
line (10 mM); 100% activity is the rate of 6 mFu/s.
TABLE 2
Effect of metal chelators on P. falciparumM17 leucyl aminopeptidase
activity
Reagent Concentration (mM) Relative activity
a
Without Co(II)b With Co(II)c
%
None 100 100
o-Phenanthroline 10 0.6	 1 0.3	 0.04
1 44	 0.9 52	 0.6
0.1 96	 5 80	 3
0.01 107	 5 81	 0.6
EDTA 10 80	 5 6	 0.1
1 90	 4 88	 1
0.1 112	 6 104	 15
0.01 91	 4 93	 2
a Data reflect the mean relative activity of three assays	 S.D. (n 3).
b PfLAP not preincubated with Co(II), 100% activity rate of 51 mFu/s.
c PfLAP preincubated with 1 mM Co(II), 100% activity rate of 1710 mFu/s.
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and isoleucinewere not cleaved by rPfLAP (even at substrate con-
centrations of 200 M). Additionally, the enzyme did not cleave
substrates with small nonpolar (Gly), acid (Asp, Glu), or basic
(Arg) amino acids.
We found that the substrate H-Ala-NHMec was poorly
cleaved by rPfLAPwith kcat/Km 3.78M1 s1. Becausewe (15,
16) and others (22, 41) have shown that this substrate is effi-
ciently cleaved by aminopeptidases in soluble extracts of
malaria parasites, we compared the elution profiles of these
extracts to that of rPfLAP subjected
toHPLC size chromatography. Each
eluted fraction was analyzed for
H-Leu-NHMec- and H-Ala-MH-
Mec-cleaving activity in the presence
and absence of Co(II) (Fig. 3). The
rPfLAP resolved as a single enzy-
matic peak which, when compared
with the molecular size standards,
was calculated to be 320 kDa (Fig. 3,
top panel and inset). This elution
profile confirms that the rPfLAP
exists as a homohexamer, which is
common for M17 leucyl aminopep-
tidases (38, 39). In contrast, two
peaks of H-Leu-NHMec-cleaving
activity were detected in the soluble
extracts of malaria, one at 320 kDa
(with an identical retention time to
the rPfLAP peak) and another at 82
kDa (Fig. 3, bottom panel). The 320-
kDa enzymatic peak eluted from the
rPfLAP andmalaria extracts did not
cleave H-Ala-NHMec, and both
activities were reduced by 95% if
the fraction were not preactivated
with Co(II) before addition of sub-
strate. The enzyme eluting in the
82-kDa peak, however, was capable
of cleaving bothH-Leu-NHMec and
H-Ala-NHMec, and its activity was
not significantly affected by a prein-
cubation period with Co(II) (Fig. 3).
PfLAP Is Expressed in the Cytosol
throughout Intra-erythrocytic Devel-
opment—Intra-erythrocytic PfLAP
mRNA expression levels, shown in
Fig. 4A, are highest in the ring stage
parasites followed by the trophozo-
ite stages, with levels dropping dur-
ing the latter half of the devel-
opmental cycle. Immunoblotting
studies using sera prepared against a
synthetic PfLAP peptide (anti-M17)
detected a single protein of the
expected 68 kDa and showed that
it is expressed during all stages
of intra-erythrocytic development,
including schizonts (Fig. 4B).
FIGURE 3.HPLCgel filtration of recombinant andnative P. falciparum leucyl aminopeptidase. The rPfLAP
(3 g) (upper panel) and soluble extracts of P. falciparum parasites (15 g) (lower panel) were analyzed on a
Superdex-200 HPLC column. Fractions were activated by addition of 1 mM Co(II) for 20 min before assessing
their activity against the fluorogenic peptide substrates H-Leu-NHMec (small dashed line) and H-Ala-NHMec
(large dashed line) as outlined under “Experimental Procedures.” The solid line represents the elution of themix
of four proteins used as molecular size standards, apoferritin (440 kDa), -amylase (232 kDa), bovine serum
albumin (67 kDa), and carbonic anhydrase (29 kDa), which were monitored at A280. A plot of log (Mr) versus
elution time for these standards was linear (inset).
TABLE 3
Kinetic parameters for the hydrolysis of fluorogenic peptide
substrates by the recombinant P. falciparumM17 leucyl
aminopeptidase
Substrate kcat 103 Km kcat/Km
s1 M M1 s1
H-Leu-NHMec 39.0	 1.0 12.12	 1.04 3218
H-Phe-NHMec 1.45	 0.09 7.92	 0.51 183.1
H-Pro-NHMec 0.59	 0.02 234.91	 17.76 2.51
H-Ala-NHMec 0.2	 0.003 52.90	 2.61 3.78
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To determine the cellular location of the PfLAP protein, we
probed parasite-infected erythrocytes with antiserum prepared
against the recombinant enzyme and found immunoreactivity
localized to the parasite cytoplasm (Fig. 5A). Confirmation of
this localization for the PfLAP was obtained using a live fluo-
rescence assay to visualize the presence of PfLAP-GFP fusion
protein in P. falciparum erythrocytic stages transfected with
the PF14_0439-GFP construct (Fig. 5B). All intra-erythrocytic
stages, including segregating merozoites, displayed diffuse
staining indicative of a cytoplasmic localization; however, the
intensity of the staining was greatest in the early and late tro-
phozoite stages.
Inhibitors of rPfLAP Are Also Inhibitors of P. falciparum
Growth in Vitro—The ability of bestatin and two derivatives,
nitrobestatin and bestatin methyl ester, to inactivate rPfLAP
was compared with their antimalarial activity against P. falcip-
arum clone D10 in culture (Table 4). Bestatin was a potent
inhibitor of rPfLAP with a Ki  25 nM and, as demonstrated
previously (10, 16), was active against the intra-erythrocytic
development of malaria parasites, displaying an IC50 value of
14.9 M. Nitrobestatin exhibited an almost 10-fold greater
inhibitory activity against rPfLAP than bestatin, but its antima-
larial activity was only slightly increased (IC50  8 M). The
bestatin methyl ester derivative, on the other hand, exhibited a
6-fold lower inhibitor value for rPfLAP (Ki  138 nM), but its
killing activity against the parasites in culture was only slightly
less than bestatin (IC50 20.5 M).
DISCUSSION
All living cells maintain a closely regulated balance between
protein catabolism and anabolism. The final step in protein
catabolism provides free amino acids to the cell and is per-
formed by various aminopeptidases; M17 leucyl aminopepti-
dases are among themost predominant within the cytosol (42).
The presence of an M17 leucyl aminopeptidase in malaria is
thus not surprising, and these proteases likely perform the same
housekeeping function as in any other cell; however, in malaria
parasites the enzymemust take on the additional chore of free-
ing amino acids from peptides sent to the cytosol from the DV
where the rapid turnover of host hemoglobin takes place. Reg-
ulating the cellular pool of amino acids is not only essential for
protein synthesis in malaria but also for maintaining the cor-
rect osmotic balance within the host erythrocyte (8) and for
setting up a gradient by which amino acids that are not pro-
vided by hemoglobin in sufficient quantities can be drawn
from the external environment (9, 10). Thus, malaria amin-
opeptidases are critical to the survival of the parasite within
the host erythrocyte.
Because of their unusually high A/T richness (81% in P. fal-
ciparum, 36), functional expression of malarial antigens in het-
erologous systems has proven difficult; mRNA transcripts are
often unstable or prematurely terminated (43). Mehlin et al.
(44) assessed the expression of 1000 P. falciparum genes (lack-
ing transmembrane regions) in E. coli, but only 337 genes gave
rise to recombinant proteins, and of these, only 63 were soluble in
aqueous buffers (6.3% soluble expression rate). To overcome this
problem, we synthesized the M17 leucyl aminopeptidase with a
codon usage that was expected to favor expression in the yeast P.
pastoris (and removed potential glycosylation sites as this orga-
nism tends to hyper-glycosylate), but neither the full-length
gene nor a truncated form lacking the N-terminal extension
containing the asparagine-rich LCR was expressed in this sys-
tem. The truncated form of the same gene was accommodated
by insect cells transformed by baculovirus, and functionally
active enzyme was expressed in soluble form that was isolated
by affinity chromatography onNi-NTA-agarose.Wehave since
obtained functionally active rPfLAP in E. coli BL21 (DE3) by
transforming these with the P. pastoris-optimized truncated
gene in the expression vector pTrcHisB (Invitrogen). However,
the purified recombinant protein obtained using this system
rapidly lost enzymatic activity (within 2 days) at 4 °C. In con-
trast, the insect cell-produced enzyme retained activity for
greater than 4 weeks when stored in neutral to slightly alkaline
buffers (pH 7.3 to 8.2) at 4 °C.
The expressed rPfLAP resolved at 60 kDa on reducing SDS-
PAGE but HPLC size chromatography showed that the soluble
protein exhibits a molecule size in the region of 320 kDa con-
sistent with the enzyme forming a homohexamer, which has
been described for several other leucyl aminopeptidases such as
that of Leishmania mexicana (45), E. coli (46), pig kidney (47),
and bovine lens (39). Removal of theN-terminal extension con-
taining the asparagine-rich LCR clearly did not prevent correct
folding of the protein nor the ability of the monomers to com-
bine into hexamers. The N-terminal extension containing the
asparagine-rich LCR varies in length and amino acid composi-
tion between the various human and rodent malarias, but the
N- and C-terminal domains, particularly the latter that houses
the catalytic apparatus, are highly conserved (80–85%). All the
residues involved in substrate binding are absolutely conserved
FIGURE 4. Expression of the P. falciparumM17 leucyl aminopeptidase in
the intra-erythrocytic stages of development. A, total RNA isolated from
stage-specific parasites was probed with a DNA fragment corresponding to
the full-length M17 leucyl aminopeptidase DNA (LAP) before being stripped
and re-probed with the P. falciparum S28 RNA probe (28S) to ensure equal
sample loading in the lanes. B, protein extracts from stage-specific parasites
were resolved on reducing SDS-polyacrylamide gels (10%), transferred to
0.2-m polyvinylidene difluoride membranes, and probed with mouse anti-
M17 peptide (LAP), stripped and re-probed with anti-P. falciparum glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) monoclonal antibodies. Parasites
were synchronized using two rounds of sorbitol treatment, and stage-specific
parasites were harvested at early ring stage (R), early trophozoite stage (ET), late
trophozoite (LT) ,and schizont stage (S).
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between the malaria species; and therefore, the enzymes
derived from the rodent malaria would be expected to have
identical substrate specificities to that of the rPfLAP character-
ized in this study. These comparisons are relevant because
Ramjee et al. (48) demonstrated that the cysteine protease of
rodent malaria P. berghei (berghepain-2) displayed significant
differences in substrate specificity to its ortholog from the
humanmalaria P. falciparum (falcipain 2, FP-2), and thus ques-
tioned the appropriateness of rodent malarial models for test-
ing the in vivo antimalarial activity of inhibitors directed at
FP-2.
Also consistent with itsmembership of theM17 leucyl amin-
opeptidase family was the substrate preference of rPfLAP for
N-terminally exposed hydrophobic amino acids, most mark-
edly leucine. The enzyme did not cleave aliphatic (Val and Ile),
small nonpolar (Gly), acid (Asp and Glu), or basic (Arg) amino
acids. Of particular interest, however, was our enzyme kinetic
data showing the relative inability of rPfLAP to cleave N-termi-
nal alanine (850-fold lower than leucine). This differential
preference has been described for other M17 leucyl aminopep-
tidase, for example those isolated fromLeishmania species (45).
However, we have demonstrated previously that soluble
extracts of P. falciparummalaria contained neutral aminopep-
tidase activity capable of effectively cleaving both H-Leu-
NHMec andH-Ala-NHMec (16, 21), and similar activities have
been reported by Florent et al. (22) using the same substrates.
HPLC size separation chromatography revealed that the spe-
cific H-Leu-NHMec-cleaving activity in malaria extract resides
in a 320-kDa peak with an identical retention time to the
rPfLAP and that its activity is similarly enhanced by the metal
ionCo(II). On the other hand, a separate aminopeptidase elutes
in an 82-kDa peak that cleaves bothH-Leu-NHMec andH-Ala-
NHMec anddoes not exhibit activation in the presence ofmetal
ions. Accordingly, we suggest that the 320 kDa in malaria
extracts represents the native formof the hexamericM17 leucyl
aminopeptidase. Considering its substrate specificity and
molecular size, we suggest that the 82-kDa peak represents the
M1 alanyl aminopeptidase described by Florent et al. (22) and
that the peakmay contain a combination of the soluble forms of
92 and 68 kDa that are processed from the 122-kDamembrane-
bound parent molecule. Definitive proof of this suggestion,
however, awaits further studies, including production of a func-
tional recombinant M1 enzyme for comparative studies.
Both Northern blotting and immunoblotting studies show
that PfLAP is expressed by all intra-erythrocytic developmental
stages of P. falciparum. Our Northern blot data support gene
expression profiling studies using microarrays that showed
PfLAP mRNA levels are highest in the early trophozoite stages
and decrease during the latter half of the cycle (49–51). Le Roch
et al. (49) found that genes with similar expression profiles dur-
ing the intra-erythrocytic development of the parasite could be
assigned to one of 15 clusters that correlated with the function
of the gene products in the malarial cell. Thus, genes that were
maximally expressed in the ring and trophozoite stages and
declined in the latter stages of the life cycle were assigned to
clusters 5–7 and included proteins involved in protein synthe-
sis. PfLAP was assigned to cluster 6, and its expression was
closely aligned with that of the cysteine protease falcipain-2
(PF11_0165) andplasmepsins (PF14_0174; PF14-_0075), which
is consistent with its involvement with these enzymes in the
turnover of host hemoglobin. But whether the PfLAP plays
additional functions in the latter developmental stages where
expression is lower but still present within schizonts and segre-
gated merozoites is unknown. A role for an aminopeptidase in
red cell invasion was suggested by studies by Olaya and Was-
serman (52), and our laboratory has shown that the number of
ring stage parasites in cultures 24 h after addition of schizont-
infected erythrocytes to uninfected cells was reduced by the
presence of bestatin (16). However, because the IC50 value of
this effect was 25 M (two times higher than that which pre-
vents trophozoite and schizont growth, see this study and Ref.
16), we suspected that this observation was because of inhibi-
tion of schizont growth rather than cell invasion.
Quantitative analysis of mRNA levels during the intra-eryth-
rocytic stages of the parasite indicate that levels of M17 amin-
opeptidase mRNA transcripts are18-fold greater than those
of the M1 aminopeptidase (49). Our analysis of malaria para-
site-soluble extracts (80% trophozoites) by HPLC size chro-
matography as described above (Fig. 3) do not suggest such a
FIGURE 5. Localization of the P. falciparumM17 leucyl aminopeptidase in
the intra-erythrocytic parasites. A, immunofluorescence assays were car-
ried out using air-dried P. falciparum-infected red blood cells fixed with ace-
tone. Cells were probed with mouse anti-M17 peptide (1/250) and then Cy2-
conjugatedgoat anti-mouseantibodies.B, transgenicP. falciparum strainD10
parasites expressing the complete M17 leucyl aminopeptidase linked to
green fluorescent protein were visualized in a live fluorescence assay. The
parasite nuclei were visualized with Hoechst dye (0.5 g/ml). Samples were
viewed on an Axioscope 2 Mot (Zeiss) equipped with a Zeiss 63x/1.4 Plan
Apochromat lens. Images were captured with an Axiocam MRm camera
(Zeiss) using Axiovision AC software (Zeiss). BF, bright field; DAPI,
4,6-diamidino-2-phenylindole.
TABLE 4
Inhibition of recombinant P. falciparumM17 leucyl aminopeptidase
activity and blocking of the in vitro growth of the parasite (DC10
strain) by bestatin and its derivatives
Inhibitor
Inhibitory activity
against recombinant
P. falciparum LAPKi
(nM)
Inhibition of the
in vitro growth
of P. falciparum
IC50 (M)
Bestatin 25 14.87
Nitrobestatin 2.7 8
Bestatin methyl ester 138 20.5
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large difference between the levels of expression of these two
aminopeptidases; the total fluorogenic units calculated for the
320-kDa peak containing the M17 PfLAP is almost three times
lower than that detected in the 82-kDa peak, which we believe
represents the M1 alanyl aminopeptidase. However, the tran-
scriptome and proteome data did not always correlate in the
study of Le Roch et al. (49), who suggested that transcription
and translation may not be tightly associated. Perhaps, differ-
ences in the rate of mRNA turnover or stability may also
account for the observed discrepancies between themRNAand
enzymatic data.
Wehave shownpreviously that the aminopeptidase inhibitor
bestatin can block the growth in culture of both human, P.
falciparum, and rodent, P. chabaudi chabaudi, malaria (21).
Bestatin exerts its greatest inhibitory effects on trophozoites
(16), a timewhen cellularmetabolism is at its peak, hemoglobin
degradation is at its highest, and expression of PfLAP is ele-
vated. In this studywe show that bestatin is a potent inhibitor of
rPfLAP with an inhibitory constant (Ki) of 25 nM; however, its
derivative, nitrobestatin, exhibits almost a 10-fold greater
inhibitory activity (Ki 2.7 nM). Correlating with its greater
anti-rPfLAP inhibitory activity, nitrobestatin was also a more
potent inhibitor of P. falciparum growth in culture, displaying
an IC50 of 8 M, although this was less than 2-fold better than
bestatin, with an IC50 of 14.87 M. Studies have demonstrated
that the uptake of bestatin by erythrocytes in vitro is very slow,
0.3% permin, as entry is entirely dependent on passive diffusion
across the red blood cell plasma membrane (53). Because
nitrobestatin possesses an additional electronegative group,
passive transfer of this derivative would be expected to be
slower compared with bestatin and may account for its low
antimalarial activity relative to its anti-rPfLAP activity. Inter-
estingly, although bestatin methyl ester (Ki  138 nM) was
6-fold less inhibitory of rPfLAP compared with bestatin and
50-fold less compared with nitrobestatin, it showed a surpris-
ingly high relative antimalarial killing activity in culture (IC50 of
20.5 M). Replacement of the C-terminal carboxyl group of
bestatin (COOH) with a methyl ester (COOCH3) greatly
increases its hydrophobicity and therefore its ability to perme-
ate cellular membranes (54). Thus, despite its lower anti-
rPfLAP effects, bestatin methyl ester would penetrate both
erythrocyte and parasite membranes more easily than the
hydrophilic bestatin and nitrobestatin. Another important fac-
tor that may influence the rate of transport of these dipeptide
analogs into the infected cell is their possible interaction with
specialized transport channels and receptors that are inserted
into the erythrocyte and parasitophorus membranes by the
malaria parasites for the two-way trafficking of amino acids and
other solutes (55). Overall, however, it must be pointed out that
the inhibition constants for inhibition of PfLAP, Ki, for each of
these compounds are much lower than their IC50 values, which
may indicate that they do not gain access to the target enzyme
easily.
Our data support the idea that the M17 rPfLAP is a target of
the bestatin-mediated killing of malaria parasites. However,
they do not exclude the possibility that this inhibitor kills
malaria parasites by targeting other enzymes. Bestatin, bestatin
methyl ester, and nitrobestatin can inhibit the aminopeptidase
activities in both the 320- and 82-kDa peaks obtained in our
HPLC gel filtration analysis of malaria extracts (not shown),
which clearly demonstrates that these aminopeptidase inhibi-
tors have an additional target enzyme in the parasite. The most
obvious other candidate is the M1 alanyl aminopeptidase that
has also been suggested to be involved in the liberation of free
amino acids from the fragments of digested hemoglobin and
probably works in concert with the M17 PfLAP. It is not sur-
prising that blocking these enzymes would have such a dra-
matic effect on the growth in culture of malaria given that
leucine and alanine constitute 24% of the amino acids of the
hemoglobin (15) (without considering other hydrophobic
amino acids, for example phenylalanine, methionine, and cys-
teine, that these enzymesmay be responsible for releasing from
hemoglobin-derived peptides). Two othermalaria aminopepti-
dases, a prolyl aminopeptidase and aspartyl aminopeptidase,
can be detected in soluble extracts of P. falciparum parasites
using specific fluorogenic substrates andmay be responsible for
cleaving the bulky hydrophobic amino acid proline and the
acidic amino acids (aspartic acid and glutamic acid) within
hemoglobin, respectively, that are not cleaved by M17 or M1
aminopeptidases. However, the activity of these more special-
ized aminopeptidases is not affected by bestatin or its deriva-
tives, thereby excluding them as targets of the antimalarial
activity of these inhibitors (data not shown).
Much of the evidence supporting the hemoglobin digestive
pathway as a therapeutic target comes from studies involving
the major DV endopeptidases, the aspartic proteases (plas-
mepsins I, II, and IV), and cysteine proteinases (falcipains 2, 2,
and 3) (7, 12). Indeed, inhibitors against the malarial aspartic
proteases prevent parasite growth in culture (56) and cure
malaria in a P. chabaudi chabaudimousemodel (57). Similarly,
the cysteine protease inhibitor E64 prevents the development
of cultured parasites by blocking the hydrolysis of hemoglobin
and also cures Plasmodium vinckei-infected mice (58, 59).
These inhibitors induce the characteristic swelling of the DV
because of the accumulation of undegraded hemoglobin (60,
61). More recent gene disruption studies of both the aspartic
and cysteine protease gene families have revealed the synergis-
tic nature of these enzymes (62–64). However, disruption stud-
ies by Omara-Opyene et al. (62) demonstrated that the loss of
any single DV plasmepsin or in combination (plasmepsin IV-I
double knock out) is in itself insufficient to produce a lethal
phenotype. Inactivated genes cannot only be compensated by
other DV plasmepsins but also by members of the falcipain
protease gene family. Similarly, disruption of any of the DV
falcipains known to be involved in hemoglobin digestion can be
compensated by increased expression of other members of the
family (63, 65). Liu et al. (11) demonstrated that a knock out
involving a combination of genes from both protease families
(disrupted falcipian-2 on a plasmepsin IV/I double knock-out
back round) had a negative but nonlethal effect on parasite
growth in medium when parasites were cultured in medium
containing isoleucine as the sole exogenously added amino
acid. Collectively, these results suggest significant redundancy
in the proteolytic systems within the DV and, more impor-
tantly, indicate that in order for therapeutic strategies to be
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successful inhibitors should be capable of targeting both fami-
lies of proteases in combination (11).
Importantly, malaria parasites express only one class of the
M17 and M1 aminopeptidases and therefore redundancy of
function is somewhat restricted. At present, specific inhibitors
of each these aminopeptidases are not available to assess the
extent to which theymay compensate for each other within the
parasite cytosol. However, studies are underway to examine
this issue using transgenic and antisense techniques to knock
out or knock down the production of each enzyme. It must also
be mentioned that various other exopeptidases, including
dipeptidases, tripeptidases, and carboxypeptidases, are
expressed bymalaria parasites and presumably work in concert
with the aminopeptidases to release amino acids from hemo-
globin (13).
Bestatin is a dipeptide analog first discovered as an antibiotic
with aminopeptidase inhibitory activity in culture filtrates of
the bacterium Streptomyces olivoreticuli (66). Amajor target of
bestatin-mediated inhibition inmammals is aminopeptidaseN,
anM1 alanyl membrane aminopeptidase localized to the intes-
tinal brush border and on the surface of many immune cells
where it is better known as CD13 (67). Bestatin induces immu-
nomodulatory effects on certain immune effector cells but has
very low toxicity in experimental animals and humans (68–71)
and, consequently, has been formulated for the safe therapeutic
treatment of certain cancers such as squamous cell carcinoma
in humans (53, 72).
The data presented in this study provides a meaningful bio-
chemical explanation for the antimalarial activity of broad
spectrum aminopeptidase inhibitors, such as bestatin. These
dipeptide analogs will be useful scaffolds on which novel small
molecule inhibitors could be designed to potently and selec-
tively inhibit either or both the P. falciparum M17 leucyl and
M1 alanyl aminopeptidases (10). An additional challenge now
exists for medicinal chemists to design related compounds that
can readily cross the erythrocyte and parasite membranes by
either simple or facilitated diffusion to gain access to their
targets. Availability of the functionally active rPfLAP
described in this study, coupled with the simple and rapid
fluorogenic enzymatic readout, will be invaluable for screen-
ing these derivatives or for directing high throughput
screening of inhibitors in small-molecule banks. Acquiring
functionally active recombinant M1 alanyl aminopeptidase
is a priority in our laboratory so that this screening can be
carried out with both enzymes simultaneously.
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Supp. Figure 1. Comparison of the primary sequences of the human and rodent 
malaria M17 leucyl aminopeptidases. The primary sequence of the P. falciparum 
M17 leucyl aminopeptidase (PF14_0439) was aligned with its ortholog from P. 
yoelii (MALPY00521), P. berghei (PB_RP3746) and P. c. chabaudi 
(PC_RP1908).  Conservation between amino acids is indicated by asterisk and 
dots in the alignment. The arrow indicates the beginning of the truncated rPfLAP. 
The asparagine-rich LCRs in the N-terminal extension of the malaria sequences 
are indicated each in bold and underlined. The less-conserved N-terminal 
domain is in normal font, while the more conserved C-terminal region is 
presented in bold and italics. LAPs bind two zinc ions that 
are pentahedrally-coordinated within the active site. The residues binding the 
metal ions are conserved; zinc 1 is bound by Asp 379, Asp 459 and Glu 461 
while zinc 2 is bound by Lys 374, Asp 379, Asp 399 and Glu 461 (all are red and 
underlined). The conserved Lys 386 (blue) and Arg 463 (green) act as an 
electrophile and proton donor, respectively. 
 
 28
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P. berghei         ------------------------------------------------------------ 
P. yoelii          MYLTQLKIKFVGKIFEDKFYKNINKRYYFYNIKHNQKQNFFSFFISNKIKNKNNYNSEYR 60 
P. c. chabaudi     MYLIRLNINSVDKISEN-----IIKRYYFYSLKANTKKSFSTFFISNNIKNKNNYNSVCC 55 
P. falciparum      MYFSSLCKFLP-----------ISEKEKIYLNIVKKRFCKSNIYYNNNNNNIINYNKRGL 49 
                                                                                
 
P. berghei         ------------------NFSKTIKKFYSTNN-IKNFNISFSKFEKMSLKVPQVINLDPT 41 
P. yoelii          EFRTFNTYQYQKDKIESLNFLKKVKRFYSINNNIENSNISFLKLKKMSLNVPQVISLDPT 120 
P. c. chabaudi     EFP-----QFSKDKTQFLTGSKIIKNFYSINN-KENSNSSFTKFEKMASKVPQVNSLDPA 109 
P. falciparum      KFY------------PFCNNLKKNINFVNINNKKGINFHSINKERKMASEVPQVVSLDPT 97 
                                     .  *   .* . **       *: * .**: :**** .***: 
 
P. berghei         VLPVNYTTPIDDIEIVLKDGIKESCNFDDGLAIFLVNSKSEKDNGNTKISSQIKDSKINE 101 
P. yoelii          VLPVNYTTPINDINIVLKDSVKECCNFDDDIVIFLVHSKSDKDNGNMKIGSQIKDSKINE 180 
P. c. chabaudi     VLPINYTTPFDDVKVEVKDSGKDGCTFDDGLVLFLVHSASEKEKGSLKISSNIKDSKINE 169 
P. falciparum      SIPIEYNTPIHDIKVQVYD-IKGGCNVEEGLTIFLVNNPG-KENGPVKISSKVNDKNVSE 155 
                    :*::*.**:.*::: : *  *  *..::.:.:***:. . *::*  **.*:::*.::.* 
 
P. berghei         FLSK-NDDIFNGKLGTFKSFYMANEKNKYINLSFIRCGTIDEEMTEFEIRKIVSSLVQIL 160 
P. yoelii          FLSK-NEDIFNGKLGTFKSFYISNDKNKYINLSFIRCGTIDEEMSEFEIRKIVSSLVQIL 239 
P. c. chabaudi     FLSN-NDDIFNGKIGTPKSFYISNEKNKYVNLTFIRCGGVDEEMTECEIRKIAPSLAQVL 228 
P. falciparum      FLKDENMEKFNVKLGTSKHFYMFNDNKNSVAVGYVGCGSV-ADLSEADMKRVVLSLVTML 214 
                   **.. * : ** *:** * **: *:::: : : :: ** :  :::* :::::. **. :* 
 
P. berghei         HDNKSVSTSIIFEIGINESLFRFFLETVFYEYVVDERFKSND------NKS--SGNSENM 212 
P. yoelii          HDNKSVATSIIFEIGINESLFRFFLETVFYEYVADERFKSTDKVDKVDNKSDGSGSAENM 299 
P. c. chabaudi     HDNKPTSASIIFEIDINESLFRFFLETVFYESIVDERFKSTDKAS---NKH--SSNSANM 283 
P. falciparum      HDNKLSKLTVVFEINVDKNLFRFFLETLFYEYMTDERFKSTDK----------NVNMEYI 264 
                   ****    :::***.:::.********:*** :.******.*           . .   : 
 
P. berghei         KNLQIFLRNYNNNYNKQVKKSRTYFMGTYFASQLISAPSNYCNPVSLANVSVELAEKLNL 272 
P. yoelii          KSLEIFLKNYNNDYVKQVDKSRTYFMGTYFASQLISAPSNYCNPVSLANVAVELAEKLNL 359 
P. c. chabaudi     KNLHIFLKNHNANYNKEVEKARIYFMGTHFACQLTSAPSNYCNPVSLANVAVELAEKLNL 343 
P. falciparum      KHLGVYINNADT-YKEEVEKARVYYFGTYYASQLIAAPSNYCNPVSLSNAAVELAQKLNL 323 
                   * * :::.* :  * ::*.*:* *::**::*.** :***********:*.:****:**** 
 
P. berghei         ECKILGIKELENLKMGAYLSVGKGSMYPNRFIHLTYKGKGDIKKKIALVGKGITFDSGGY 332 
P. yoelii          ECKILGVKELEELKMGAYLSVGKGSMYPNRFIHLTYKGKGDIKKKIALVGKGITFDSGGY 419 
P. c. chabaudi     EHKILGIKELEELKMGAYLSVGKGSMYPHRFIHLTYKGKGEIKKKIAFVGKGITFDSGGY 403 
P. falciparum      EYKILGVKELEELKMGAYLSVGKGSMYPNKFIHLTYKSKGDVKKKIALVGKGITFDSGGY 383 
                   * ****:****:****************::*******.**::*****:************ 
 
P. berghei         NLKASPGSMIDLMKFDMSGCAAVLGCAYCIGSIKPENVEVHFLSAVCENMVSKNSYRPGD 392 
P. yoelii          NLKASPGSMIDLMKFDMSGCAAVLGCAYCIGSIKPENVQVHFLSAVCENMVSKNSYRPGD 479 
P. c. chabaudi     NLKAAPGSLIELMKFDMGGCAAVLGSAYCIGTIKPEHVEVHFISALCENMISENAYRPGD 463 
P. falciparum      NLKAAPGSMIDLMKFDMSGCAAVLGCAYCVGTLKPENVEIHFLSAVCENMVSKNSYRPGD 443 
                   ****:***:*:******.*******.***:*::***:*::**:**:****:*:*:***** 
 
P. berghei         IITASNGKTIEVGNTDAEGRLTLADALVYAENIGVDHIIDIATLTGAMLYSLGTSYAGVF 452 
P. yoelii          IITASNGKTIEVGNTDAEGRLTLADALVYAEKIGVDHIIDIATLTGAMLYSLGTSYAGVF 539 
P. c. chabaudi     IITASNGKTIEVGNTDAEGRLTLADALVYAEKIGVDHIIDIATLTGAMLFSLGTSYAGVF 523 
P. falciparum      IITASNGKTIEVGNTDAEGRLTLADALVYAEKLGVDYIVDIATLTGAMLYSLGTSYAGVF 503 
                   *******************************::***:*:**********:********** 
 
P. berghei         GNDNKLINKILESSKSSNEPVWWLPIIKEYRASLNSKYADINNISSNVKASSVVASLFLN 512 
P. yoelii          GNDNKLINKILESSETSNEPVWWLPIIKEYRESLNSKYADINNISSNVKASSVVASLFLK 599 
P. c. chabaudi     GNDEKLINKILASSKSSSEPVWWLPIIKDYRPCLNSRLADINSXPSGNKASSIIASLFLN 583 
P. falciparum      GNNEELINKILNSSKTSNEPVWWLPIINEYRATLNSKYADINNISSSVKASSIVASLFLK 563 
                   **:::****** **::*.*********::**  ***: ****. .*. ****::*****: 
 
P. berghei         EFIQSTSWAHIDIAGVAWNFKDRKPKGFGVRLLSEFILNHSI 554 
P. yoelii          EFIKSTSWAHIDIAGVAWNFKDRKPKGFGVRLLSEFILNHSI 641 
P. c. chabaudi     EFVQSTSWAHIDIAGACWNYIDRKPTGYGVRLLSEYVLSHSI 625 
P. falciparum      EFVQNTAWAHIDIAGVSWNFKARKPKGFGVRLLTEFVLNDAL 605 
                   **::.*:********..**:  ***.*:*****:*::*..:: 
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